FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311752067> ?p ?o ?g. }

• W4311752067 abstract "Abstract Background Prolongation of the PR interval is a common finding among competitive athletes. However, further investigations should be performed when the PR interval is markedly prolonged. We report the case of a young male athlete with a late progressive congenital form of autoimmune-mediated atrioventricular block. Case presentation A 26-year-old male athlete was referred to our center because of a significant prolongation of the PR interval (PR=400 ms), firstly found at the age of 7 years in a preparticipation screening and then confirmed when he was 10 years old. He has been playing soccer for 6 hours/week without symptoms or limitations. His personal remote medical history was unremarkable, he did not have a family history of sudden cardiac death, channelopathies, or cardiomyopathies. Vital parameters and physical examination were normal. Blood test results were within the limits, with negative inflammation indexes and normal thyroid function. Ambulatory 12-lead ECG monitoring, including a training session to assess the chronotropic response to exercise, showed a 1st and 2nd type 1 AV block with narrow QRS without pauses and a shortening of the PR interval during the training session, also confirmed by exercise testing. After three months of detraining, no variation in the PR interval was observed. Echocardiography and cardiac magnetic resonance were normal, as well as genetic testing. Finally, we assessed the autoimmunity status of the patient and his mother, given the potential association between damage induced by anti-Ro/SSA antibodies and AV block and we found maternal seropositivity only, compatible with a late progressive congenital form of autoimmune AV bock. Accordingly, no circulating anti-Ro/SSA-autoantibodies were found in the athlete and we did not recommend immuno-modulating therapy. Considering the absence of symptoms and of cardiac, laboratory and genetic abnormalities, no circulating autoantibodies in the patient and the stability of the PR interval, the athlete was deemed eligible for sports competition. We advised him yearly follow-up visits to exclude the possibility of conduction disturbance progression. During the follow-up period he has continued to practice competitive sports without events. Discussion According to current recommendations, 1st degree AV block (up to 399 ms) and 2nd degree type 1 AV block can be considered physiological adaptations to exercise, especially if they disappear during exercise and detraining. Otherwise, further investigations are recommended to exclude abnormalities associated with sudden cardiac death in athletes, such as structural heart diseases, primary electrical diseases and autoimmunity. The most recognized form of autoimmune AV block is congenital (neonatal lupus). Growing evidence supports the existence of a late progressive congenital form, in which the conduction system injury is mediated by transplacental passage of antibodies produced by the mother and cross-reacting with calcium channels in the fetus, with a subclinical presentation in utero/at birth/in the neonatal phase and a manifest conduction disease later in life. Finally, autoimmune AV block can be acquired, in this case autoantibodies are found in the patient only and immuno-modulating therapy can be considered. In our case, maternal only seropositivity supported the hypothesis of a late progressive congenital form." @default.
• W4311752067 created "2022-12-28" @default.
• W4311752067 creator A5004217601 @default.
• W4311752067 creator A5004563169 @default.
• W4311752067 creator A5019375497 @default.
• W4311752067 creator A5044840935 @default.
• W4311752067 creator A5046408327 @default.
• W4311752067 creator A5053891335 @default.
• W4311752067 creator A5071891434 @default.
• W4311752067 creator A5088571005 @default.
• W4311752067 date "2022-12-14" @default.
• W4311752067 modified "2023-09-28" @default.
• W4311752067 title "807 MATERNAL ANTI-RO/SSA AUTOANTIBODIES AND PROLONGED PR INTERVAL IN A COMPETITIVE ATHLETE" @default.
• W4311752067 doi "https://doi.org/10.1093/eurheartjsupp/suac121.702" @default.
• W4311752067 hasPublicationYear "2022" @default.
• W4311752067 type Work @default.
• W4311752067 citedByCount "0" @default.
• W4311752067 crossrefType "journal-article" @default.
• W4311752067 hasAuthorship W4311752067A5004217601 @default.
• W4311752067 hasAuthorship W4311752067A5004563169 @default.
• W4311752067 hasAuthorship W4311752067A5019375497 @default.
• W4311752067 hasAuthorship W4311752067A5044840935 @default.
• W4311752067 hasAuthorship W4311752067A5046408327 @default.
• W4311752067 hasAuthorship W4311752067A5053891335 @default.
• W4311752067 hasAuthorship W4311752067A5071891434 @default.
• W4311752067 hasAuthorship W4311752067A5088571005 @default.
• W4311752067 hasBestOaLocation W43117520671 @default.
• W4311752067 hasConcept C111773187 @default.
• W4311752067 hasConcept C126322002 @default.
• W4311752067 hasConcept C130049864 @default.
• W4311752067 hasConcept C164705383 @default.
• W4311752067 hasConcept C178697064 @default.
• W4311752067 hasConcept C1862650 @default.
• W4311752067 hasConcept C187212893 @default.
• W4311752067 hasConcept C206179267 @default.
• W4311752067 hasConcept C2775935837 @default.
• W4311752067 hasConcept C2777953023 @default.
• W4311752067 hasConcept C2781054738 @default.
• W4311752067 hasConcept C2781179581 @default.
• W4311752067 hasConcept C71924100 @default.
• W4311752067 hasConcept C84393581 @default.
• W4311752067 hasConceptScore W4311752067C111773187 @default.
• W4311752067 hasConceptScore W4311752067C126322002 @default.
• W4311752067 hasConceptScore W4311752067C130049864 @default.
• W4311752067 hasConceptScore W4311752067C164705383 @default.
• W4311752067 hasConceptScore W4311752067C178697064 @default.
• W4311752067 hasConceptScore W4311752067C1862650 @default.
• W4311752067 hasConceptScore W4311752067C187212893 @default.
• W4311752067 hasConceptScore W4311752067C206179267 @default.
• W4311752067 hasConceptScore W4311752067C2775935837 @default.
• W4311752067 hasConceptScore W4311752067C2777953023 @default.
• W4311752067 hasConceptScore W4311752067C2781054738 @default.
• W4311752067 hasConceptScore W4311752067C2781179581 @default.
• W4311752067 hasConceptScore W4311752067C71924100 @default.
• W4311752067 hasConceptScore W4311752067C84393581 @default.
• W4311752067 hasIssue "Supplement_K" @default.
• W4311752067 hasLocation W43117520671 @default.
• W4311752067 hasOpenAccess W4311752067 @default.
• W4311752067 hasPrimaryLocation W43117520671 @default.
• W4311752067 hasRelatedWork W2013002880 @default.
• W4311752067 hasRelatedWork W2018794923 @default.
• W4311752067 hasRelatedWork W2058761320 @default.
• W4311752067 hasRelatedWork W2080632332 @default.
• W4311752067 hasRelatedWork W2088488472 @default.
• W4311752067 hasRelatedWork W2117909396 @default.
• W4311752067 hasRelatedWork W2118995160 @default.
• W4311752067 hasRelatedWork W2780898805 @default.
• W4311752067 hasRelatedWork W4247809369 @default.
• W4311752067 hasRelatedWork W4256288161 @default.
• W4311752067 hasVolume "24" @default.
• W4311752067 isParatext "false" @default.
• W4311752067 isRetracted "false" @default.
• W4311752067 workType "article" @default.